董事、高级管理人员离职管理制度 浙江向日葵大健康科技股份有限公司 董事、高级管理人员离职管理制度 第一条 为规范浙江向日葵大健康科技股份有限公司（以下简称"公司"）董 事、高级管理人员离职相关事宜，确保公司运营稳定，保障股东权益，依据《中华 人民共和国公司法》（以下简称"《公司法》"）及《浙江向日葵大健康科技股份有 限公司章程》（以下简称"《公司章程》"）等有关法律法规，结合公司实际情况， 制订本制度。 （三）独立董事辞任导致董事会或其专门委员会中独立董事所占比例不符合法 律法规或《公司章程》规定，或者独立董事中欠缺会计专业人士。 董事提出辞任的，公司应当在提出辞任之日起六十日内完成补选，确保董事会 及其专门委员会构成符合法律法规和《公司章程》的规定。 第二条 本制度适用于公司所有董事、高级管理人员的离职管理。 第三条 公司董事、高级管理人员任期按《公司章程》规定执行，董事、高级 管理人员可以在任期届满前提出辞任。董事、高级管理人员辞任应当向公司提交书 面辞职报告，辞职报告中应说明辞职原因。 董事辞任的，自公司收到通知之日辞任生效。高级管理人员辞任的，自董事会 收到辞职报告时生效。公司收到董事、高级管理人员的 ...

委托理财管理制度 浙江向日葵大健康科技股份有限公司 第二条 本制度适用于公司，经公司同意后公司控股子公司可进行委托理财活动。 第三条 本制度所称委托理财是指在相关法律法规及政策允许、有效控制投资风险 的前提下，以提高资金使用效率、增加现金资产收益为原则，对闲置资金通过商业银 行理财、信托理财及其他理财工具进行运作和管理，在确保安全性、流动性的基础上 实现资金的保值增值。 第四条 公司从事委托理财应坚持"规范运作、防范风险、谨慎投资、保值增值" 的原则，以不影响公司正常经营和主营业务的发展为先决条件。 第五条 委托理财的资金为公司闲置资金，不得挤占公司正常运营和项目建设资金。 募集资金不得用于委托理财（现金管理除外）。 第六条 公司进行委托理财时，应当严格按照本制度规定的决策程序、报告制度和 监控措施履行，并根据公司的风险承受能力确定投资规模。 委托理财管理制度 第一章 总 则 第一条 为规范浙江向日葵大健康科技股份有限公司（以下简称"公司"）的委托 理财业务的管理，有效控制风险，提高资金运作效率和效益，维护公司及股东利益， 依据《中华人民共和国证券法》（以下简称"《证券法》"）、《深圳证券交易所创业板股 票上 ...

突发事件处理制度 浙江向日葵大健康科技股份有限公司 突发事件处理制度 第一章 总 则 第一条 为提高浙江向日葵大健康科技股份有限公司（以下简称"公司"）处 置突发事件和保障生产经营安全的能力，最大限度地预防和减少突发事件及其造成 的损害，维护公司正常的生产经营秩序和企业稳定，保障广大投资者合法利益，促 进公司全面、协调、可持续发展，根据 《中华人民共和国公司法》《中华人民共和 国证券法》《中华人民共和国突发事件应对法》、中国证监会《证券、期货市场突 发事件应急预案》及《公司章程》《信息披露管理制度》等有关规定，结合公司实际 情况，特制订本制度。 第二条 本制度所称突发事件是指突然发生的、有别于日常经营的、已经或可 能会对公司的经营、财务状况以及对公司的声誉、股价产生严重影响的、需要采取应 急处置措施予以应对的偶发性事件。 第三条 公司应对突发事件工作实行预防为主、预防与应急相结合的原则。 第 1 页 共 7 页 1、公司大股东出现重大风险，对公司造成重大影响； 2、大股东之间存在纷争诉讼，或出现明显分歧； 3、公司与社会、股东、员工之间存在纷争诉讼； 4、公司董事及高管人员涉及重大违规甚至违法行为； 5、决策 ...

提供财务资助管理制度 公司财务资助对象为公司合并报表范围内的、持股比例超过50%的控股子公 司，且该控股子公司其他股东中不包含公司的控股股东、实际控制人及其关联人 的，应当经董事长审议通过。 第三条 公司及其控股子公司存在下列情形之一的，应当参照本制度的规定 执行： （一）在主营业务范围外以实物资产、无形资产等方式对外提供资助； （二）为他人承担费用； 浙江向日葵大健康科技股份有限公司 提供财务资助管理制度 第一章 总则 第一条 为规范浙江向日葵大健康科技股份有限公司（以下简称"公司"） 对外提供财务资助的行为，防范财务风险，完善公司治理与内控管理，根据《中 华人民共和国证券法》《深圳证券交易所创业板股票上市规则》（以下简称"《创 业板上市规则》"）《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》等法律法规及《公司章程》等内部制度的有关规定，制定本 制度。 第二条 本制度所称对外提供财务资助，是指公司及其控股子公司有偿或者 无偿对外提供资金、委托贷款等行为，但不包括资助对象为公司合并报表范围内 的、持股比例超过50%的控股子公司，且该控股子公司其他股东中不包含公司的 控股股东、实际控制 ...

授权管理制度 浙江向日葵大健康科技股份有限公司 授权管理制度 第一条 为了加强浙江向日葵大健康科技股份有限公司（以下简称"公司"）授 权管理工作，确保公司规范化运作，保护公司、股东和债权人的合法权益，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称 "《证券法》"）《深圳证券交易所创业板股票上市规则》（以下简称"《创业板股票上市 规则》"）等法律、行政法规、部门规章以及《浙江向日葵大健康科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，结合公司实际情况，特制定本制度。 第二条 本制度所称授权是指：公司股东会对董事会的授权；董事会对董事长、 总经理的授权以及公司具体经营管理过程中的必要的授权。 第三条 授权管理的原则是，在保证公司、股东和债权人合法权益的前提下，提 高工作效率，使公司经营管理规范化、科学化、程序化。 第四条 股东会是公司的最高权力机构，有权对公司重大事项作出决议。 第五条 董事会是公司的经营决策机构。董事会应当建立严格的审查和决策程序， 在对重大事项做出决定前应当组织有关专家、专业人员进行评审。 第六条 在股东会授权范围内，下列交易事项（《创业 ...

远期外汇交易管理制度 浙江向日葵大健康科技股份有限公司 远期外汇交易管理制度 第一章 总则 第五条 公司进行远期外汇交易业务须遵守以下原则： 第一条 为规范浙江向日葵大健康科技股份有限公司（以下简称"本公司"、 "公司"）远期外汇交易业务的操作、防范国际贸易业务中的汇率风险、保证汇 率风险的可控性及强化公司内部的风险控制，根据《中华人民共和国公司法》《中 华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《上市公司信息 披露管理办法》及《浙江向日葵大健康科技股份有限公司章程》（以下简称"《公 司章程》"）等相关规定，结合公司具体实际，特制定本制度。 第二条 本制度所称远期外汇交易是指为满足正常生产经营需要，在银行办 理的规避和防范汇率风险的远期外汇交易业务，包括远期购（结售）汇业务、人 民币外汇掉期业务等。 第三条 远期购（结售）汇业务是指与银行签订远期购（结售）汇合同，约 定将来办理购买或售汇的外汇币种、金额、汇率和期限，到期再按照该远期合同 约定的币种、金额、汇率办理购买或售汇的业务。人民币外汇掉期业务是指在委 托日同时与银行约定两笔金额一致、买卖方向相反、交割日期不同的人民币对同 一外币的买卖交易 ...

第一章 总 则 第一条 为提高浙江向日葵大健康科技股份有限公司（以下简称"公司"）规 范运作水平，增强信息披露的真实性、准确性、完整性和及时性,加大对年报信息披 露责任人的问责力度，提高年报信息披露的质量和透明度，根据《公开发行证券的 公司信息披露内容与格式准则第2号——年度报告的内容与格式》《上市公司信息 披露管理办法》和《深圳证券交易所创业板股票上市规则》等相关法律、法规、规 范性文件及《浙江向日葵大健康科技股份有限公司章程》（以下简称"《公司章程》"）、 《信息披露管理制度》的有关规定，结合公司实际情况,制定本制度。 第二条 本制度是指年报信息披露工作中有关人员不履行或者不正确履行职 责、义务以及其他个人原因，对公司造成重大经济损失或不良社会影响时的追究与 处理制度。 第三条 本制度适用范围：公司董事、高级管理人员、公司控股股东及实际控 制人、子公司负责人、公司内部负责年报数据提供的部门负责人及直接经办人、与 年报信息披露有关的工作人员。 年报信息披露重大差错责任追究制度 浙江向日葵大健康科技股份有限公司 年报信息披露重大差错责任追究制度 （三）违反《公司章程》《信息披露管理制度》以及公司其他内控制度, ...

外部信息使用人管理制度 第八条 对于无法律法规依据的外部单位年度统计报表等报送要求，公司应拒 绝报送。 第九条 公司各部门、所属子公司及其他相关人员依据法律法规的要求向外部 单位或个人提供公司尚未公开的重大信息、财务数据等，需要将报送的外部单位相 浙江向日葵大健康科技股份有限公司 外部信息使用人管理制度 第一条 为加强浙江向日葵大健康科技股份有限公司（以下简称"公司"）定 期报告及重大事项在编制、审议和披露期间，公司外部信息使用人的管理,依据《中华 人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、《浙 江向日葵大健康科技股份有限公司章程》（以下简称"《公司章程》"）及《上市公 司信息披露管理办法》（以下简称"《信息披露管理办法》"）等有关规定，制定本办 法。 第二条 本制度适用于公司及控股子公司、董事、高级管理人员。 第三条 本制度所指信息，是指根据《证券法》第五十二条的规定，涉及公司 的经营、财务或者对公司证券的市场价格有重大影响的尚未公开的信息。 第四条 本制度所指外部信息使用人，是指根据法律法规有权向公司要求报送 信息的特定单位所涉人员，包括但不限于各级政府主管部门等确因工作需要须 ...

[Section I Important Notes, Table of Contents, and Definitions](index=2&type=section&id=Section%20I%20Important%20Notes%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides crucial preliminary information, including management assurances, the report's structure, and definitions of key terms [Important Notes](index=2&type=section&id=Important%20Notes) The board, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness, while forward-looking statements are not substantive commitments - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the report content[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section outlines the report's structured content, comprising eight main chapters covering essential company and financial information - The report contains eight main chapters with a clear structure[7](index=7&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms used in the report, including company, subsidiary, industry, and financial concepts, for accurate understanding - The report includes detailed definitions of company, subsidiary, industry, and financial terms[10](index=10&type=chunk) [Section II Company Profile and Key Financial Indicators](index=6&type=section&id=Section%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section introduces the company's basic information and presents its key financial performance and position indicators for the reporting period [1. Company Profile](index=6&type=section&id=1.%20Company%20Profile) The company, Zhejiang Xiangrikui Great Health Technology Co., Ltd., is listed on the Shenzhen Stock Exchange under stock code 300111 - The company's stock abbreviation is 'Xiangrikui', stock code **300111**, listed on the Shenzhen Stock Exchange[11](index=11&type=chunk) [2. Contact Person and Information](index=6&type=section&id=2.%20Contact%20Person%20and%20Information) Contact details for Board Secretary Li Lan are provided to facilitate communication with investors - Contact information for Board Secretary Li Lan has been disclosed[12](index=12&type=chunk) [3. Other Information](index=6&type=section&id=3.%20Other%20Information) The company's registered address, office address, website, email, and information disclosure details remained unchanged during the reporting period - The company's contact information, information disclosure, and registration status remained unchanged during the reporting period[13](index=13&type=chunk)[14](index=14&type=chunk)[15](index=15&type=chunk) [4. Key Accounting Data and Financial Indicators](index=7&type=section&id=4.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company experienced a decline in operating revenue and net profit for H1 2025, with a significant drop in net profit after non-recurring items 2025 Semi-Annual Key Accounting Data and Financial Indicators | Indicator | Current Period (RMB) | Prior Year Same Period (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 144,420,083.69 | 157,542,789.35 | -8.33% | | Net Profit Attributable to Shareholders of Listed Company | 1,160,651.10 | 1,804,470.08 | -35.68% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 44,806.22 | 809,328.22 | -94.46% | | Net Cash Flow from Operating Activities | 8,403,114.63 | 13,034,924.70 | -35.53% | | Basic Earnings Per Share (RMB/share) | 0.001 | 0.001 | 0.00% | | Diluted Earnings Per Share (RMB/share) | 0.001 | 0.001 | 0.00% | | Weighted Average Return on Net Assets | 0.17% | 0.27% | -0.10% | | **Period-end Indicators** | **End of Current Period (RMB)** | **End of Prior Year (RMB)** | **Change from Prior Year-end (%)** | | Total Assets | 981,809,554.42 | 999,118,426.12 | -1.73% | | Net Assets Attributable to Shareholders of Listed Company | 687,439,839.72 | 686,244,996.62 | 0.17% | [5. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=7&type=section&id=5.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) The company reported no differences in net profit and net assets between domestic and overseas accounting standards during the period - The company had no differences in accounting data under domestic and overseas accounting standards during the reporting period[17](index=17&type=chunk)[18](index=18&type=chunk) [6. Non-recurring Gains and Losses and Amounts](index=7&type=section&id=6.%20Non-recurring%20Gains%20and%20Losses%20and%20Amounts) Total non-recurring gains and losses for the period were RMB 1,115,844.88, primarily from asset disposals, government subsidies, and wealth management income 2025 Semi-Annual Non-recurring Gains and Losses and Amounts | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and Losses from Disposal of Non-current Assets | 177,327.51 | Mainly gains from disposal of leased assets upon termination during the reporting period | | Government Subsidies Included in Current Period's Profit and Loss | 1,665,905.66 | Mainly government subsidies received during the reporting period | | Gains and Losses from Changes in Fair Value and Disposal of Financial Assets and Liabilities Held | 174,463.01 | Mainly income from wealth management during the reporting period | | Other Non-operating Income and Expenses Apart from the Above | -3,512.97 | | | Less: Income Tax Impact | 339,048.92 | | | Impact on Minority Interests (After Tax) | 559,289.41 | | | **Total** | **1,115,844.88** | | - The company has no other profit and loss items that meet the definition of non-recurring gains and losses, nor has it classified non-recurring gains and losses as recurring gains and losses[21](index=21&type=chunk) [Section III Management Discussion and Analysis](index=9&type=section&id=Section%20III%20Management%20Discussion%20and%20Analysis) This section analyzes the company's main business, core competitiveness, financial performance, non-core operations, asset and liability status, investments, and risks [1. Main Business Activities During the Reporting Period](index=9&type=section&id=1.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company focuses on pharmaceutical manufacturing, specializing in anti-infective, cardiovascular, and digestive system drugs, facing revenue and profit declines due to market and competitive pressures [1. Industry Overview](index=9&type=section&id=1.%20Industry%20Overview) The pharmaceutical manufacturing industry (C27) faces revenue and profit pressure, with chemical raw materials and products manufacturing profit declining by 9.0% YoY in H1 2025 - The company operates in the pharmaceutical manufacturing industry (C27), with total profit of the chemical raw materials and chemical products manufacturing industry decreasing by **9.0% year-on-year** from January to June 2025[23](index=23&type=chunk) - The pharmaceutical industry is undergoing a structural adjustment from scale growth to quality and efficiency, with accelerated innovation transformation and continuously strengthened drug approval standards[24](index=24&type=chunk) - The company insists on 'refining and strengthening' its API products, featuring pharmaceutical preparations, and holds a leading position in the production of clarithromycin API[25](index=25&type=chunk) [2. Main Business Segments](index=9&type=section&id=2.%20Main%20Business%20Segments) The company's core business is in pharmaceuticals, focusing on R&D, production, and sales of anti-infective, cardiovascular, and digestive system drugs - The company's main business focuses on the pharmaceutical sector, covering R&D, production, and sales of anti-infective, cardiovascular, and digestive system drugs[26](index=26&type=chunk) - Clarithromycin API is a major component of the company's operating revenue, sold to domestic and international markets[26](index=26&type=chunk) [3. Company's Main Products and Uses](index=9&type=section&id=3.%20Company%27s%20Main%20Products%20and%20Uses) The company's product portfolio includes anti-infective, cardiovascular, and digestive system drugs, each with specific therapeutic applications - The company's product line covers anti-infective, cardiovascular and digestive system three major categories of drugs[27](index=27&type=chunk)[29](index=29&type=chunk) - Clarithromycin API and tablets are used to treat various infections; lacidipine is used to treat hypertension; simvastatin tablets are used for hyperlipidemia and coronary heart disease; omeprazole sodium and famotidine are used for digestive system diseases[27](index=27&type=chunk)[29](index=29&type=chunk) [4. Business Model](index=10&type=section&id=4.%20Business%20Model) The company operates on a 'purchase-to-order' procurement and 'production-to-order' manufacturing model, complemented by diversified sales channels for APIs and preparations - The procurement model is 'purchase-to-order', maintaining safety stock and strictly adhering to GMP standards[30](index=30&type=chunk) - The production model is 'production-to-order', with the quality department supervising the entire production process[30](index=30&type=chunk)[31](index=31&type=chunk) - Sales models are diversified, with APIs sold through direct sales and foreign trade companies, and pharmaceutical preparations sold through bidding and distributor agency models[31](index=31&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk)[35](index=35&type=chunk) [5. H1 Operating Performance](index=11&type=section&id=5.%20H1%20Operating%20Performance) In H1 2025, operating revenue decreased by 8.33% and net profit by 35.68% YoY, despite growth in lacidipine dispersible tablet sales 2025 Semi-Annual Operating Performance Overview | Indicator | Amount (RMB 10,000) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 14,442.01 | -8.33% | | Net Profit Attributable to Shareholders of Listed Company | 116.07 | -35.68% | - Pharmaceutical preparation business was affected by declining market demand and lower competitor prices, leading to a significant decline in sales of anti-infective products, but sales of lacidipine dispersible tablets increased by **39.03% year-on-year**[36](index=36&type=chunk) - The company continued to strengthen R&D investment, and domestic production drug registration and marketing authorization applications for Roxadustat Capsules, Glucosamine Sulfate Capsules, and Lacidipine Tablets have been accepted[37](index=37&type=chunk) [2. Core Competitiveness Analysis](index=12&type=section&id=2.%20Core%20Competitiveness%20Analysis) The company's core strengths include an integrated industrial chain, strong product and brand recognition, and continuous innovation in process technology [1. Industrial Chain Advantage](index=12&type=section&id=1.%20Industrial%20Chain%20Advantage) The company benefits from an integrated pharmaceutical industrial chain, enhancing efficiency, diversifying risks, and strengthening overall competitiveness - The company possesses a complete integrated industrial chain from pharmaceutical intermediates to APIs and preparations, covering anti-infective and antihypertensive drugs[39](index=39&type=chunk) - Industrial chain integration has improved resource allocation efficiency, diversified risks from single product price fluctuations, and enhanced product competitiveness[39](index=39&type=chunk) [2. Product and Brand Advantage](index=12&type=section&id=2.%20Product%20and%20Brand%20Advantage) Key products are included in national essential drug and medical insurance lists, supported by numerous approvals and a commitment to social responsibility - Clarithromycin tablets and lacidipine dispersible tablets have been successfully included in the National Essential Drug List and National Medical Insurance Catalog, significantly expanding market potential[39](index=39&type=chunk) - The company has obtained **13 preparation approval numbers** and **5 API registration numbers**, with **3 varieties** in the Class A Medical Insurance Catalog and **4 varieties** in the National Essential Drug List[39](index=39&type=chunk) - The company pioneered braille labeling on product packaging and completed a pilot program for age-friendly instructions for lacidipine dispersible tablets, enhancing brand image and social responsibility[40](index=40&type=chunk) [3. Process Technology Advantage](index=12&type=section&id=3.%20Process%20Technology%20Advantage) Beide Pharmaceutical leads in clarithromycin API quality and holds numerous patents, with key products passing consistency evaluation to boost market competitiveness - Beide Pharmaceutical has accumulated core technologies in the production of anti-infective and antihypertensive drugs, with clarithromycin API quality leading domestically[41](index=41&type=chunk) - Clarithromycin tablets and simvastatin tablets have passed consistency evaluation, which helps enhance market competitiveness[41](index=41&type=chunk) 2025 Semi-Annual New Utility Model Patents | No. | Patent Name | Patent No. | Patent Type | Validity Period | | :--- | :--- | :--- | :--- | :--- | | 1 | A powder conveying mechanism for azithromycin dispersible tablet press | ZL202420589288X | Utility Model | 10 years from January 7, 2025 | | 2 | A powder feeding mechanism for capsule production line | ZL2024208712910 | Utility Model | 10 years from March 11, 2025 | | 3 | A lacidipine tablet press | ZL2024205892894 | Utility Model | 10 years from April 4, 2025 | | 4 | A tablet suction mechanism for simvastatin tablet press | ZL2024205892911 | Utility Model | 10 years from April 4, 2025 | | 5 | A drying device for clarithromycin | ZL2024208712959 | Utility Model | 10 years from May 9, 2025 | | 6 | A capsule production line | ZL2024208712925 | Utility Model | 10 years from May 9, 2025 | [3. Main Business Analysis](index=12&type=section&id=3.%20Main%20Business%20Analysis) Operating revenue and costs declined, with significant reductions in sales and R&D expenses, while investment cash flow decreased due to wealth management product purchases [Overview](index=13&type=section&id=Overview) This section provides an overview of the company's main business, referencing previous discussions on its pharmaceutical focus and operational highlights - The main business overview refers to the content in '1. Main Business Activities During the Reporting Period'[43](index=43&type=chunk) [Year-on-Year Changes in Key Financial Data](index=13&type=section&id=Year-on-Year%20Changes%20in%20Key%20Financial%20Data) Operating revenue decreased by 8.33%, sales expenses by 39.85%, and R&D investment by 42.62%, while financial expenses increased by 32.38% 2025 Semi-Annual Key Financial Data YoY Change | Indicator | Current Period (RMB) | Prior Year Same Period (RMB) | YoY Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 144,420,083.69 | 157,542,789.35 | -8.33% | | | Operating Cost | 114,970,967.75 | 120,858,612.71 | -4.87% | | |

浙江向日葵大健康科技股份有限公司 法定代表人：吴少钦 主管会计工作负责人：潘卫标 会计机构负责人（会计主管人员）：吴丹琳 汇总表 第 1页 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名 称 | 占用方与上 市公司的关 | 上市公司 核算的会 | 年期 2025 初占用资 | 2025年1-6月 占用累计发 生金额（不含 | 年 2025 1-6 占用资金的 | 月 | 年 2025 1-6 月偿还累计 | 年 2025 6 月份期末 占用资金 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 联关系 | 计科目 | 金余额 | 利息） | 利息(如有) | | 发生金额 | 余额 | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | | | | | | | | | | | | 非 经 营 性 | | 其附属企业 | | | | | | | | | | | 占 ...